Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 10/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 10/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 10/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000115 | 0.84 | SLC40A1 (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL701285 | 0.83 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL10000119 | 0.81 | CYP19A1 (0.38) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3021830 | 0.75 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL12789731 | 0.74 | TDP1 (0.53) | PDE4BPDE4APDE4CPDE4DTDP1 | |
| SCHEMBL10000103 | 0.74 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13247008 | 0.73 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL10000108 | 0.73 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL10000102 | 0.72 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3017476 | 0.71 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160386-B1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | ALLERGAN INC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8124774-B2 | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124774-B2 | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100197729-A1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | ALLERDAN, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197729-A1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | ALLERDAN, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2008147788-A1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | ALLERGAN, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197729-A1 | THERAPEUTIC ((PHENYL)IMIDAZOLYL)METHYLQUINOLINYL COMPOUNDS | GOT2, COQ8A, OAT | ADRA2A 905/4885ADRA2B 1168/4885ADRA2C 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.